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Abstract
AIM
To provide new insights in treatment of colitis and 
ischemia and reperfusion in rats using stable gastric 
pentadecapeptide BPC 157. 
METHODS
Medication [BPC 157, L-NAME, L-arginine (alone/
combined), saline] was bath at the blood deprived colon 
segment. During reperfusion, medication was BPC 157 
or saline.  We recorded (USB microscope camera) vessel 
presentation through next 15 min of ischemic colitis (IC-
rats) or reperfusion (removed ligations) (IC + RL-rats); 
oxidative stress as MDA (increased (IC- and IC + RL-
rats)) and NO levels (decreased (IC-rats); increased (IC 
+ RL-rats)) in colon tissue. IC + OB-rats [IC-rats had 
additional colon obstruction (OB)] for 3 d (IC + OB-
rats), then received BPC 157 bath. 
RESULTS
Commonly, in colon segment (25 mm, 2 ligations 
on left colic artery and vein, 3 arcade vessels within 
ligated segment), in IC-, IC + RL-, IC + OB-rats, 
BPC 157 (10 μg/kg) bath (1 mL/rat) increased vessel 
presentation, inside/outside arcade interconnections 
quickly reappeared, mucosal folds were preserved and 
the pale areas were small and markedly reduced. BPC 
157 counteracted worsening effects induced by L-NAME 
(5 mg) and L-arginine (100 mg). MDA- and NO-levels 
were normal in BPC 157 treated IC-rats and IC + RL-
rats. In addition, on day 10, BPC 157-treated IC + OB-
rats presented almost completely spared mucosa with 
very small pale areas and no gross mucosal defects; 
the treated colon segment was of normal diameter, and 
only small adhesions were present.
CONCLUSION
BPC 157 is a fundamental treatment that quickly 
restores blood supply to the ischemically injured area 
and rapidly activates collaterals. This effect involves the 
NO system. 
Key words: Ischemic colitis; Blood flow rescue; 
Collaterals; BPC 157; L-NAME; L-arginine; Oxidative 
stress; NO; Rats
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Core tip: We rescued rat ischemic colitis. The gastric 
pentadecapeptide BPC 157, which has been used in 
clinical trials for ulcerative colitis, exerted rapid cyto-
protective endothelium rescue against the disabled left 
colic artery and vein after blood deprivation via two 
ligations and during reperfusion (ligations removed). By 
bypassing obstructions, quickly rescuing blood supply, 
rapidly activating collaterals, and restoring arcade 
interconnections, as a new integrative beneficial effect, 
BPC 157 prevented the occurrence of pale lesions 
without mucosal folds and normalized the levels of 
NO and MDA, two oxidative stress markers, in tissues. 
BPC 157 showed effectiveness over the NO-system 
background, immobilized (L-NAME + L-arginine), 
(over)stimulated (L-arginine) or blocked (L-NAME). 
Likewise, later application of BPC 157 in a bath 
treatment to rats with pertinently obstructed vessels 
that underwent additional colon obstruction for three 
days produced a similar beneficial effect.
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INTRODUCTION
The colon is particularly susceptible to insufficient 
vascular perfusion[1]. In this work, we focused on the 
prototype cytoprotective anti-ulcer peptide stable gastric 
pentadecapeptide BPC 157, which has been used in 
trials for ulcerative colitis and now for multiple sclerosis, 
in the treatment of colitis and ischemia in rats[2-8], 
seeking new insights into ischemic colitis (IC), ischemia 
and reperfusion and therapy. The  harmful events were 
on the left colic artery and vein, such as two ligations 
(IC rats) or injuries from removed ligations (RL) (IC + 
RL rats) (there was always gross vessel presentation 
failure), and the combination of two obstructions, 
ligation of the vessels and additional colon obstruction 
(OB) (IC + OB rats). IC was assessed at short (minutes) 
(IC rats, IC + RL rats) or more prolonged (3- and 10-d) 
intervals (IC + OB rats).  
The main focus of the intervention was that BPC 157 
rapidly activates collaterals due to its particular direct 
and rapid effect on vessel presentation, the bypassing of 
one or more of the vascular obstructions and thereby 
achieving a therapeutic effect. 
The next focus was on NO-system, the effect of NO 
system agents in IC rats, NOS blocker L-NAME and/or 
NOS substrate, L-arginine[2-8]; in colon tissue, assessing 
NO levels and oxidative stress (MDA levels) (as result 
of the lysis of endothelial cells[9,10]) and ischemia/
reperfusion injury, both as a spontaneous course [when 
blood supply was deprived via ligation (IC rats)] and 
a more exaggerated course (after ligation removal 
(IC + RL rats)) in immediate post-ligation time. 
Notably, although the NO system is largely implicated 
in stomach cytoprotection and colitis lesions[2-4], the 
application of L-NAME (a vasoconstrictor)[11] and/or 
L-arginine (a vasodilator)[11] has not been investigated 
with respect to the immediate presentation of the 
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blood vessels after a segment of left colic artery and 
vein was occluded by two ligations. By contrast, BPC 
157 largely interacts with the NO system in various 
models and species, as shown in cytoprotection 
studies, in particular, studies using both L-NAME and 
L-arginine as individual agents or in combination[2-4]. 
The shared essential effect of cytoprotective 
agents, which was originally noted in the stomach, is 
regarded as a rapid endothelial protective mechanism 
that can be used to prevent and resolve adjacent 
ischemic mucosal lesions[12-16]. It may be possible to 
extend the rapidly occurring beneficial cytoprotective 
effect of these agents and to use them to prevent 
ischemic colitis lesions, in which specific activation of 
the collateral circulation can circumvent obstructions 
and reestablish the continuity of blood flow. This effect 
must be a long-lasting effect that is exerted within the 
immediate post-injury time period (a factor that has not 
investigated in vascular studies of ischemic colitis[17-19]); 
it must also be applicable in the later period, even after 
a considerable period of additional colon obstruction has 
occurred. 
Unlike standard cytoprotective agents that exhibit 
only prophylactic effectiveness (shared limitation of 
activity)[9,10,12,13,15,16,20], BPC 157 represents a prototype 
of a more effective class of cytoprotective agents with 
both prophylactic and therapeutic ability[7,16]. BPC 157, 
as a novel mediator of Robert’s cytoprotection[2-8,20], is 
native and stable in human gastric juice and maintains 
gastrointestinal mucosal integrity[2-8]. BPC 157 addi-
tionally maintains the gross presentation of stomach 
blood vessels under harmful conditions[21,22] when 
these vessels would otherwise disappear. In addition to 
its beneficial effect, BPC 157 counteracts the vessels’ 
disappearance[21,22]. Furthermore, this additional rapid 
cytoprotective vascular recovery and presentation leads 
to a consequent strong angiogenic effect in subsequent 
days[2,22-28]. Its angiogenic response[2,22-28] in combination 
with its healing effects and its interaction with several 
molecular pathways[11,25-29] is more profound than the 
angiogenesis of standard anti-ulcer agents[23].
Previously, BPC 157 also counteracts colitis (in 
various models of colitis[30-35]) and its complications, such 
as fistulas[36-38], failed healing of anastomoses[30,34,38-40] 
and other gastrointestinal lesions that were otherwise 
poorly healed[2-8], given parenterally or per-orally. For 
further clarification and to show a direct beneficial 
effect, medication was given once as a bath to the 
segment of left colic artery and vein obstructed by 
two ligations. Consequently, beneficial effects can be 
directly related to the reversal of obstructive injury 
outcome consequences, in both early (IC rats; IC + 
RL rats) and later (IC + OB rats) periods, and may 
be triggered shortly after injury initiation [IC rats 
(vessels ligation)]; IC + RL rats (ligations removed, 
exaggerated reperfusion)) or later, with an already-
advanced injury course (IC+OB rats). Then, to focus on 
the initial ligation-course (blood vessel presentation), 
pentadecapeptide BPC 157, L-NAME, L-arginine were 
given to in IC rats alone and/or in combination. 
Alternatively, BPC 157 was given post-ligation.  At 
these points, colon tissue levels of MDA and NO were 
assessed, and results showed NO colon tissue levels 
and oxidative stress (MDA) and ischemia/reperfusion 
injury during the ligation course; these effects were 
even worse after ligation removal and post-ligation. 
Likewise, as a therapeutic effect that is also applicable 
in the later period, BPC 157 was given to the rats with 
ligated left colic artery and vein, and they underwent 
additional colon obstruction for three days (IC + OB 
rats).
MATERIALS AND METHODS
Animals
Male Albino Wistar rats, 200 g b.w., were used in the 
experiments. The animals were randomly assigned to 
groups of at least 6 rats per group. The experiments 
were approved by the local ethics committee. The 
surgical procedure was performed in rats that had food 
and water ad libitum before the procedure and until 
the end of the experiment, and assessments were 
performed by an observer unaware of the treatments 
used.   
Drugs
The pentadecapeptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-
Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, M.W. 1419, named 
BPC 157, which is a part of the sequence of human 
gastric juice protein, coded BPC, freely soluble in 
water at pH 7.0 and in saline, was prepared (Diagen, 
Ljubljana, Slovenia) as described before[2-7,34]. L-NAME 
and L-arginine were commercially purchased (Sigma, 
United States). 
Experimental protocol and assessment
The purpose of the experiments was to counteract 
both immediate and late consequences of vessel 
ligation injury in blood-deprived colon segments and to 
produce and assess rapid cytoprotective recovery.
Initial assessment in rats with two ligations at the left 
colic artery and vein for 15 min (IC rats) and in rats that 
had two ligations at the left colic artery and vein for 15 
min, and then were reperfused for the next 15 min (IC + 
RL rats)
The surgery was conducted in deeply anesthetized rats. 
A segment of the left colic artery and vein was occluded 
by 2 ligations (Premilene 7/0, Braun), 3 arcade vessels 
within the ligated segment, the 25-mm blood-flow-
deprived descending colon segment. Medication (/kg, 1 
mL bath/rat) applied to the 25-mm blood-flow-deprived 
colon segment, included BPC 157 (10 μg), the NOS 
blocker L-NAME (5 mg), the NOS substrate L-arginine 
(100 mg) alone or in combination or a saline bath of 
equal volume (control) at 1 min of ligation time.  In 
rats that received two ligations of the left colic artery 
8467 December 28, 2017|Volume 23|Issue 48|WJG|www.wjgnet.com
Duzel A et al. BPC 157 and colitis/ischemia in rats
8468 December 28, 2017|Volume 23|Issue 48|WJG|www.wjgnet.com
gation time or at 15 min reperfusion time, oxidative 
stress in the collected tissue samples was assessed 
by quantifying thiobarbituric acid-reactive species 
(TBARS) as malondialdehyde (MDA) equivalents. The 
tissue samples were homogenized in PBS (pH 7.4) 
containing 0.1 mmol/L butylated hydroxytoluene (BHT) 
(TissueRuptor, Qiagen, United States) and sonicated for 
30 s in an ice bath (Ultrasonic bath, Branson, United 
States). Trichloroacetic acid (TCA, 10%) was added to 
the homogenate, the mixture was centrifuged at 3000 
rpm for 5 min, and the supernatant was collected. 
Then, 1% TBA was added, and the samples were boiled 
(95 ℃, 60 min). The tubes were then kept on ice for 
10 min. Following centrifugation (14000 rpm, 10 min), 
the absorbance of the mixture at the wavelength of 532 
nm was determined. The concentration of MDA was 
read from a standard calibration curve plotted using 
1,1,3,3’-tetraethoxy propane (TEP). The extent of lipid 
peroxidation was expressed as MDA using a molar 
extinction coefficient for MDA of 1.56 × 105 mol/L/cm. 
The protein concentration was determined using a 
commercial kit. The results are expressed in nmol per 
mg of protein.
NO determination in colon tissue
At the end of the experiment and at 15 min ligation 
and vein for 15 min, the ligations were removed, and 
the area was then reperfused for next 15 min (IC + 
RL rats), medication at that colon segment during 
reperfusion included BPC 157 (10 μg) and saline bath 
of equal volume (control) at 1 min of reperfusion time. 
Using a camera attached to a USB microscope 
(Veho discovery VMS-004 deluxe), we recorded the 
vessel presentation (fulfilled/appearance or cleared 
out/disappearance) between the arcade vessels on the 
ventral and dorsal sides throughout the following 15 min 
[with regard to the point immediately before therapy (as 
100%)] at selected time points before and after therapy 
[see the assessment shown in Figure 1 (IC rats)]. The 
extent of pale areas without mucosal folds was recorded 
upon colon opening and after sacrifice as % of total 
area of the deprived colon segment (IC rats) or as % 
of total area of the reperfused colon segment (IC + 
RL rats). Oxidative stress was assessed by quantifying 
thiobarbituric acid (TBA) reactivity as malondialdehyde 
(MDA) equivalents and by determining the NO levels in 
the colon tissue. Representative tissue sections were 
processed for further histological analysis as described 
previously[2-7,34]. 
Oxidative stress
At the end of the experiment and at 15 min of li-
Arcade
outside
ligation (0)
Arcades inside ligation (1, 2, 3)
Arcade
outside
ligation (4)
OUT-IN
Arcade 0
-Arcade 1
IN-IN
Arcade 1
-Arcade 2 IN-IN
Arcade 2
-Arcade 3
Distal
ligationProximal
ligation
IN-OUT
Arcade 3
-Arcade 4
Figure 1  Assessment of arcade vessels arcade 0; arcade 1, 2, 3; arcade 4  (dorsal colon side before the initiation of therapy, USB microscope camera). 
The ligations include three major arcades within the ligations (arcade 1, 2, 3), and thereby the possibility of bypassing both obstructions caused by the proximal and 
distal ligations (full lines) by an additional network of vessels located between the arcades (outside (arcade 0, arcade 4) and inside ligation (arcade 1, 2, 3); outside 
(arcade 0)-inside arcade 1); inside -inside(arcade 1-arcade 2; arcade 2-arcade 3); inside (arcade 3)-outside (arcade 4) (dashed lines) at the both ventral and dorsal 
sides of the colon. Note that there is no contact between inside arcade 3 and outside arcade 4. The appearance of the arcade vessels at specific time points [A (1 
minute before therapy), B (next 5 min), C (the next 5 minutes, until the 10th min), D (until the end of the 15th min)] was assessed between (1) the last arcade proximal 
to first ligation (arcade 0) at the first arcade distal to first ligation, inside the ligated segment (arcade 1) (OUT-IN) (0-1, Figure 2, ♦--, Figures 5, 6, 13, 14); (2) between 
the next arcade (arcade 2), middle arcade inside ligations (IN-IN) (1-2, Figure 2; ▲, Figures 5, 6, 13, 14) and the following arcade (2-3, Figure 2; --X--, Figures 5, 6, 
13, 14), and finally presentation to the first outside arcade distal to the second ligation (arcade 4) (IN-OUT) (3-4, Figure 2; ■, Figures 5, 6, 13, 14).
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time or at 15 min reperfusion time, we determined 
the NO levels in colon tissue samples using the 
Griess reaction (Griess Reagent System, Promega, 
United States). Sulfanilamide was added to the 
homogenized tissue, the mixture was incubated, and 
N-1-naphthylethylenediamine dihydrochloride was 
added. The Griess reaction is based on the diazotization 
reaction in which acidified nitrite reacts with diazonium 
ions and, in a further step, is coupled to N-1-na-
phthylethylenediamine dihydrochloride, forming a 
chromophoric azo derivative. Absorbance was measured 
at 540 nm, using sodium nitrite solution as a standard. 
NO levels are reported in μmol/mg protein. Protein con-
centrations were determined using a commercial kit 
(BioRad Protein DR Assay Reagent Kit, United States).
Late assessment: rats with ligated left colic artery and 
vein that underwent additional colon obstruction for 
three days (IC + OB rats) 
In deeply anesthetized rats, in addition to the left colic 
artery and vein obstruction by two ligations performed 
as described above, which resulted in a 25-mm blood-
deprived colon segment, an additional colon obstruction 
was made close to the distal ligation using a plastic 
ring 4 mm in diameter. The same BPC 157 protocol 
(/kg, 1 mL bath/rat) was applied at the 25-mm blood-
flow-deprived colon segment after the adhesions were 
gently removed. BPC 157 (10 μg) or a saline bath of 
equal volume for the controls was applied on day 3 
immediately after the ring was removed. Using a USB 
camera (Veho discovery VMS-004 deluxe) attached to a 
microscope, we recorded the vessel presentation for the 
15 min immediately following treatment, as described 
above. In a separate group of rats, the colon was 
opened and the extent of pale areas without mucosal 
folds was recorded as described previously.  At day 7 
after ring removal and bath-therapy application, the 
deprived colon segment diameter, the colon was opened, 
and pale areas without mucosal folds were assessed 
as % of total area of the deprived colon segment and 
number of gross mucosal defects. Representative tissue 
sections were processed for further histological analysis 
as described previously[2-7,34]. The severity of adhesions 
was described as previously[34,37,39,40] and scored on a 
scale of 0 to 2 (0-no adhesion; 1 - fatty tissue adhering 
to colon; 2 - small intestine adhering to colon).  
Figure 2  Progressive disappearance (A, saline bath; B, C, left) or recovery (BPC 157 bath; B, C, right) of blood vessels after ligation of the dorsal colon 
of IC rats (USB microscope camera). Ligation course before therapy (A); ligation course after therapy (B, C). A. Left colic artery and vein major arcade vessels 
obstructed by two ligations, proximal (left) and distal (right) (L), arcade vessels outside 0, 4 (black circles) or inside 1, 2, 3 (white circles), inside-outside connection 
absent (arcade 3-arcade 4) (white arrows). B. Five minutes later: inside-outside connection still absent (saline bath, left) (white arrow) or reestablished (black arrow); 
vessel presentation markedly increased (BPC 157 bath, right). C. From the 10th minute through the end of the 15th minute. Progressive vessel disappearance (saline 
bath, left) (white arrow); recovered blood vessels (BPC 157 bath, right) (black arrow).
Ligation course before therapy
0 L L
1 2 3
4
BPC 157Saline
Ligation course after therapy
A
B
C
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Statistical analysis 
Statistical analysis was performed by parametric 
one-way ANOVA with post hoc Newman-Keuls test 
and non-parametric Kruskal-Wallis and subsequent 
Mann-Whitney U-test to compare groups. Values are 
presented as the mean ± SD and as the minimum/
median/maximum. P < 0.05 was considered statistically 
significant.
RESULTS
We investigated the maintenance of vessel function 
upon the first innate reperfusion (i.e., during the 
initial recovery after blood supply was interrupted by 
the placement of two ligations on the left colic artery 
and vein (Figure 1) in IC rats. This method was also 
used much later in animals that had been subjected to 
the additional bowel obstruction (IC + OB rats) and, 
subsequently, upon massive reperfusion occurring after 
the removal of the vascular obstruction(s) (IC + RL 
rats). 
In these experiments, ischemic colitis therapy 
was administered once at early ligation time (IC rats) 
or alternatively at the early post-ligation time (IC 
+ RL rats). In other experiments, the therapy was 
administered once at a later ligation time after additional 
colon obstruction (IC + OB rats).
In general, we obtained results that showed the 
presence of increasing/decreasing collateralization 
between the arcade vessels inside and outside ligations 
or previous ligations. Subsequently, we demonstrated 
a markedly attenuated course of ischemic colitis in 
BPC 157-treated rats, IC rats, IC + RL rats, and IC + 
OB rats; conversely, an aggravated course of ischemic 
colitis was observed in L-NAME-treated rats, L-arginine-
treated rats, and in IC rats (Tables 1-3 and Figures 
1-25). 
We focused on the 25-mm blood-deprived segment 
of the descending colon. Within this ligated area, there 
were three major arcades. Thus, it was possible for both 
the proximal and distal obstructions to be bypassed 
by an additional vessel network running between the 
arcades (outside-inside ligation, outside-inside, inside-
inside and inside-outside) at both the ventral and 
dorsal sides of the colon. The particular arcade vessel 
presentation at specific subsequent time points [A 
(1 min before therapy), B (the first 5 min following 
therapy), C (the next 5 min, until the 10th min), D 
(until the end of the 15th min)] demonstrates how the 
obstructions in the tissues were bypassed. However, 
the alternative arcade pathway operated poorly at best 
in the blood-deprived colon segment. Nevertheless, 
the alternative arcade pathway was found to respond 
Figure 3  Blood vessels after ligation in IC rats (ventral colon side of the colon, before application of medication). A: Progressive disappearance of blood 
vessels (saline bath, B, ventral colon side; L-NAME, C, dorsal colon side, left) or recovery (BPC 157 bath, B, ventral colon side; L-NAME + BPC 157, C, dorsal 
colon side, right). Ligation course before therapy (A); ligation course after therapy (B, C). A. Ventral side of the colon showing the presence of an abundant collateral 
network with inside-outside contact, unlike the relatively scarce arcade collateral network and absent inside-outside contact on the dorsal side (see Figure 2). B. Five 
minutes later, the number of vessels on the ventral side of the colon is markedly decreased; the inside-outside connection is still present (saline bath, left); or vessel 
presentation is markedly increased (BPC 157 bath, right). C. From the 10th minute through the end of the 15th minute. Dorsal side of the colon showing progressive 
vessel disappearance, inside-outside contact largely absent (L-NAME bath, left) (white arrow), unlike recovered blood vessels and inside-outside contact (L-NAME+BPC 
157 bath, right (black arrow).
Ligation course before therapy
Ligation course after therapy
Saline
L-NAME L-NAME + BPC 157
 BPC 157
A
B
C
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quickly to therapy with BPC 157 vs L-NAME and 
L-arginine. 
The appearance of the vessels was assessed (see 
also Figure 1) between (1) the last arcade proximal 
to first ligation (arcade 0) and the first arcade distal 
to the ligation (or to the previous ligation) (arcade 1) 
(0-1, Figure 2, Figures 5-8, and Figures 21 and 22); (2) 
from arcade 1 to the next arcade (arcade 2), middle 
arcade inside ligations (or previous ligation) (1-2, 
Figures 2, 5-8, 21 and 22); (3) from arcade 2 to the 
next arcade (arcade 3) to the last arcade inside the 
ligations (or the previous ligation) (2-3, Figures 2, 5-8, 
21 and 22); and finally, (4) from the first arcade distal 
to the second ligation (or the previous ligation) (arcade 
4) (3-4, Figures 2, 5-8, 21 and 22). 
Initial assessment of rats that underwent two ligations 
of the left colic artery and vein for 15 min (IC rats)
Regular course (saline bath, control): Frequently, 
once major vessels were obstructed, the alternative 
arcade only partially appeared in the blood-deprived 
colon segment (Figures 2, 3, 5 and 6). After a saline 
bath was applied to the colon segment that had been 
deprived of its blood supply, arcade vessels gradually 
disappeared from the proximal to the distal arcades. 
Loose connections between inside-outside blood vessels 
were quickly seen at the dorsal side. As a result, 
there was a rapid appearance of pale flat areas and 
a rapid disappearance of mucosal folds (Table 1 and 
Figures 2-4). This dorsal/ventral side distinction may 
be related to the relatively scarce dorsal side arcade 
Table 1  Assessment of colon lesions in rats subjected to obstruction of the left colic artery and vein by two ligations for 15 min (pale 
flat areas without mucosal folds as a percentage of the area of the blood-deprived colon segment; mean ± SD) 
Medication (/kg, 1-ml bath/rat) at the 25-mm blood-flow-deprived 
colon segment
Pale areas without mucosal folds as a percentage of the area of the blood-
deprived colon segment, mean ± SD
0.9% NaCl (control) 46 ± 8
BPC 157 (10 µg)   7 ± 2a
L-NAME (5 mg)   80 ± 10a
L-arginine (100 mg) 65 ± 6a
L-NAME (5 mg) + L-arginine (100 mg) 50 ± 8
L-NAME (5 mg) + BPC 157 (10 µg)  10 ± 4a
L-arginine (100 mg) + BPC 157 (10 µg)    6 ± 2a
L-NAME (5 mg) + L-arginine (100 mg) + BPC 157 (10 µg)     8 ± 2a
The following medications or treatments (/kg, 1-mL bath/rat) were applied to the 25-mm blood-flow-deprived colon segment at 1 min post-injury: BPC 157 
(10 µg); the NOS blocker L-NAME (5 mg) and the NOS substrate L-arginine (100 mg), alone or combined; equal volume of saline bath (controls). aP < 0.05 at 
least vs control.
Duzel A et al. BPC 157 and colitis/ischemia in rats
Figure 4  Characteristic appearance of the colon in IC rats 15 min after ligation, upon colon opening before sacrifice; USB microscope camera. Extremely 
large pale areas without mucosal folds were observed after saline bath treatment (upper), in contrast to the preserved mucosal folds seen after BPC 157 bath 
treatment (lower) in rats that underwent obstruction of the left colic artery and vein for 15 min. The animals initially received bath medication consisting of saline (upper) 
or BPC 157 (lower). 
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Figure 5  IC rats. Per cent of vessels present between arcade vessels next to the proximal (arcade 0) and distal (arcade 4) ligatures and within the ligated area (arcade 
1, 2, 3) on the dorsal side of the colon at 15 min following therapy (as 100%); mean ± SD. The gross appearance of the tissue was recorded using a USB microscope 
camera. The following time points were assessed: A - after ligation and before therapy (1 min); B - 5 min after the application of medication; C - between 5 and 10 min 
after the application of medication; D - from 10 min after the application of medication until the end of the observation at 15 min. At 1 min post-injury, medication (/kg, 
1 ml bath/rat) consisting of BPC 157 (10 µg), the NOS blocker L-NAME (5 mg) and the NOS substrate L-arginine (100 mg) alone or combined, or an equal volume of 
a saline bath (controls) was applied to the 25-mm blood-flow-deprived colon segment; the rats were sacrificed at 15 minutes. For clarity, the SD is not shown on the 
graph; the SD was never higher than 10% of the mean. aP < 0.05 at least vs control.
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Figure 6  IC rats. Per cent of vessels present between arcade vessels, next to the proximal ligature (arcade 0), next to the distal ligature (arcade 4), and within the 
ligated area (arcade 1, 2, 3), on the ventral side of the colon at 15 min following therapy (as 100%); mean ± SD. The gross appearance of the tissue was recorded 
using a USB microscope camera. The following time points were assessed: A - after ligation and before therapy (1 min); B - 5 min after the application of medication; 
C - between 5 and 10 min after the application of medication; D - from 10 min after the application of medication until the end of the observation at 15 min. At 1 min 
post-injury, medication (/kg, 1 mL bath/rat) consisting of BPC 157 (10 µg), the NOS blocker L-NAME (5 mg) and the NOS substrate L-arginine (100 mg), alone or 
combined, or an equal volume of a saline bath (controls) was applied to the 25-mm blood-flow-deprived colon segment; the rats were sacrificed at 15 min. For clarity, 
the SD is not shown on the graph; the SD was never higher than 10% of the mean. aP < 0.05 at least vs control.
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a rapid disappearance of mucosal folds (Table 1 and 
Figures 2-4). This dorsal/ventral side distinction may 
be related to the relatively scarce dorsal side arcade 
collateral network; thus, once the final connection 
disappeared, it could not be easily reestablished 
(Figures 2 and 5). By contrast, at the ventral side, 
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Table 2  Assessment of colon lesions in rats subjected to two ligations of the left colic artery and vein for 15 min followed by 
reperfusion for next 15 min (IC+RL rats) (pale flat areas without mucosal folds were measured and are shown as a percentage of the 
area of the blood-deprived and the reperfused colon segment; mean ± SD)
Medication (/kg, 1 ml bath/rat) applied to the 25-mm blood-flow-
deprived and then reperfused colon segment
Pale areas without mucosal folds as a percentage of the area of the blood-flow-
deprived and then reperfused colon segment (mean ± SD)
0.9% NaCl (control) 86 ± 8
BPC 157 (10 µg) 10 ± 2a
At 1 min reperfusion time, BPC 157 (10 µg/kg, 1 mL bath/rat) or an equal volume of saline bath (control) was applied to the 25-mm blood-flow-deprived 
colon segment. aP < 0.05 at least vs control.
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Figure 7  IC + RL rats. Per cent of vessel presentation between arcade vessels, next to the previous proximal ligature (arcade 0), next to the previous distal ligature 
(arcade 4), and within the previous ligated area (arcade 1, 2, 3) on the dorsal side of the colon  at 15 min after therapy (as 100%); mean ± SD. The gross appearance 
of the tissue was recorded using a USB microscope camera. The following time points were assessed: A: After ligation and before therapy (1 min); B: 5 min after 
the application of medication; C: Between 5 and 10 min after the application of medication; D: From 10 min after the application of medication until the end of the 
observation at 15 min. At 1 min post-injury, BPC 157 (10 μg /kg, 1 mL bath/rat) or an equal volume of a saline bath (controls) was applied to the reperfused 25-mm 
colon segment; the rats were sacrificed at 15 min. For clarity, the SD is not shown on the graph; the SD was never higher than 10% of the mean. aP < 0.05 at least vs 
control.
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Figure 8  IC + RL rats. Per cent of vessels present between arcade vessels, next to the previous proximal ligature (arcade 0), next to the previous distal ligature 
(arcade 4), and within the previous ligation (arcade 1, 2, 3) on the ventral side of the colon 15 min following therapy (as 100%); mean ± SD. The gross appearance 
of the tissue was recorded using a USB microscope camera. The following time points were assessed: A: After ligation and before therapy (1 min); B: 5 min after 
the application of medication; C: Between 5 and 10 min after the application of medication; D: From 10 min after the application of medication until the end of the 
observation at 15 min.  At 1 min post-injury, medication (BPC 157, 10 μg/kg, 1 mL bath/rat) or an equal volume of a saline bath was applied to the reperfused 25-mm 
colon segment; the rats were sacrificed 15 min later. For clarity, the SD is not shown on the graph; the SD was never higher than 10% of the mean. aP < 0.05 at least 
vs control.
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collateral network; thus, once the final connection 
disappeared, it could not be easily reestablished 
(Figures 2 and 5). By contrast, at the ventral side, 
which displayed a much more abundant collateral 
network, despite a considerable decrease in inside-
inside contact, inside-outside contact persisted (Figures 
3 and 6). Along with the appearance of a considerable 
number of endothelial lesions following ligation, 
an initial blood flow deprivation and a presumably 
inadequate response, decreased NO levels (Figure 7) 
and increased MDA levels (Figure 8) were observed in 
the colon tissue. 
BPC 157 bath: By contrast, blood vessels propagated 
toward the injury obstruction, bypassing it, inter-
connecting collaterals between arcades (Figures 2, 3, 5 
and 6), recovering blood flow and thereby attenuated/
counteracted ischemia/reperfusion injury[9,10]. Mucosal 
folds were present, and there were markedly fewer 
pale areas (Table 1, Figure 4).  In particular, these 
effects all appeared in conjunction with BPC 157 
application.  
Notably, in animals that received the BPC 157 
bath, vessel presentation was markedly increased at 
the re-established inside-outside connective point in 
particular (arcade 3-arcade 4) (Figures 2, 3, 5 and 6); 
in this way, blood flow was quickly restored. In support 
of this finding, increased MDA levels and decreased NO 
levels in colon tissue were found to be normal in rats 
that received BPC 157 bath application (Figures 13 and 
14). 
NO agents, L-NAME bath, L-arginine bath: After 
the application of NO agents, particular responses 
were observed; however, neither of the responses to 
the agents was effective with respect to the extent of 
the pale areas (Table 1, Figures 3, 5 and 6). 
The application of L-NAME appeared to worsen 
the already debilitated vascular response. A larger 
proportion of the blood vessel network disappeared, 
in particular at the dorsal side (Figures 3, 5 and 6). 
Consequently, the pale areas and areas of mucosal 
fold disappearance were markedly larger (Table 1). 
L-arginine increased vessel presentation but did 
not re-establish the broken inside-outside connection 
(Figures 5 and 6). Pale areas and mucosal fold dis-
appearance were again increased (Table 1). 
Combination studies, L-NAME + L-arginine bath; 
BPC 157 + L-NAME bath; BPC 157 + L-arginine 
bath; BPC 157 + L-NAME + L-arginine bath: In 
combination, we have mutual counteraction (L-NAME + 
Outside
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Site of previous
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Figure 9  IC + RL rats (controls). Vessel presentation between arcade vessels next to the previous proximal ligature (arcade 0), next to the previous distal ligature 
(arcade 4), and within the previous ligation (arcade 1, 2, 3) on the dorsal side of the colon at 1 min reperfusion time and prior to saline bath application (upper). Similar 
vessel presentation is apparent immediately after application of a saline bath (1 mL bath/rat) (controls) to the reperfused 25-mm colon segment (lower).
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L-arginine) or presentation similar to BPC 157-treated 
rats (BPC 157 + L-NAME; BPC 157 + L-arginine; BPC 
157 + L-NAME + L-arginine) (Table 1, Figures 3, 5 and 
6).
Initial assessment of rats subjected to two ligations 
at the left colic artery and vein for 15 min, followed by 
reperfusion for next 15 min (IC + RL rats)
Regular course (saline bath, control): After a saline 
bath was applied to the reperfused colon segment, the 
arcade vessels were poorly established from proximal 
to distal arcades. The connections between inside-inside 
and inside-outside blood vessels that had been lost 
were poorly reestablished (Figures 7-9 and 11). As a 
result, there was an additional rapid appearance of pale 
flat areas and a disappearance of mucosal folds (Table 2, 
Figure 11).
BPC 157 bath: The application of BPC 157 after the 
initiation of full reperfusion with both ligations 
removed resulted in increased vessel presentation 
and arcade interconnections; the mucosal folds 
were recovered, and the pale areas were small 
and markedly reduced in area (Figures 7, 8, 10 
and 12). Consistently, the otherwise increased 
MDA and NO levels in colon tissue were found 
to be normal in rats that received BPC 157 bath 
treatment (Figures 15 and 16). 
Late assessment: rats with ligated left colic artery and 
vein that underwent additional colon obstruction for 
three days (IC + OB rats)
In these experiments, treatments were administered 
to blood-deprived colon segments that had additionally 
been challenged with ring obstruction. Notably, ligation 
of the left colic artery and vein caused extensive 
damage, and additional obstruction of the colon for 
three days led to even more severely disabled rats in 
which an extremely large pale flat area without mucosal 
folds occupied the entire ligated segment; thus, an 
advanced level of disability was present before therapy 
could be applied (Figure 19). If not reversed, this 
Figure 10  IC + RL rats (BPC 157-treated rats). Vessel presentation between arcade vessels, next to the previous proximal ligature (arcade 0), next to the previous 
distal ligature (arcade 4), and within the previous ligation (arcade 1, 2, 3) on the dorsal side of the colon at 1 minute reperfusion time and before saline bath application 
(upper). Increasing vessel presentation forming “honeycomb” structures between arcades can be seen immediately after BPC 157 treatment (BPC 157 (10 μg/kg), 2 
μg/mL bath/rat) of the reperfused 25-mm colon segment (lower).
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procedure consistently results in a perilous outcome 
(Table 3, Figures 17 and 19-22). We used the same 
BPC 157 protocol that was shown above to be effective 
when applied to the 25-mm blood-flow-deprived colon 
segment shortly after blood vessel obstruction by two 
ligations. We demonstrated that the BPC 157 treatment 
protocol was also efficacious when it was applied on day 
3, immediately after the constricting ring was removed 
(Table 3, Figures 18 and 20-22), as shown by its 
subsequent rapid effect on the appearance of the arcade 
vessels. An extended beneficial effect was also apparent 
one week later, indicating rescue from ischemic colitis. 
Immediate effect (day 3): Whereas the controls 
exhibited an increasing disappearance of arcade 
vessels, particularly at the dorsal side of the colon 
(Figures 9, 13 and 14), after BPC 157 bath treatment 
the arcade vessels vigorously reappeared together 
with interconnected collaterals between arcades, 
in particular, quickly rescuing blood flow (a finding 
especially seen at the dorsal side of the colon) (Figures 
18, 21 and 22). 
Final effect (day 10): On day 10, the blood-deprived 
colon segment contained extremely large pale areas 
without mucosal folds that occupied the entire area 
between the ligations (Table 3, Figure 20). These pale 
areas were present even outside the area that was 
ligated, and many gross mucosal defects were present 
in the enlarged colon segment (Table 2, Figure 20). 
Adhesions to the small intestine were commonly noted 
(Table 3). By contrast, the areas that had been treated 
with BPC 157 presented almost completely spared 
mucosa with very small pale areas and no gross 
mucosal defects, a colon segment of normal diameter, 
and few adhesions (Table 3, Figure 20). 
Microscopy
Microscopically, at 15 min after the beginning of 
ligation in IC rats, there was failed vascular pre-
sentation, with gross pale flat areas and the disappea-
rance of mucosal folds (Figure 2). Severe edema of 
the lamina propria and continuous diffuse edema of 
the submucosa was also evident (Figure 23A). In 
addition, there was pronounced dilatation and stasis 
in the submucosal blood vessels (Figure 23A). By 
contrast, in BPC 157-treated rats, there was recovered 
vascular presentation, with mucosal folds present and 
markedly fewer pale areas (Figure 2), mild edema 
of the lamina propria and focally present mild-to-
intermediate edema of the submucosa (Figure 23B). 
Moreover, stasis of the submucosal blood vessels was 
present, but the dilatation of veins appeared to be less 
pronounced (Figure 23B). 
In IC + RL rats after 15 min of ligation and 15 
min of full reperfusion, there was failed vascular pre-
sentation leading to an increasing number of gross 
pale flat areas and the disappearance of mucosal 
folds (Figure 12). Microscopically, even more, mucosal 
and submucosal edema, as well as more pronounced 
cyanosis, were evident. These effects were consistently 
counteracted by the application of BPC 157 after 
reperfusion initiation (Figure 24).
In IC + OB rats on day 3, immediately after re-
moving the additional colon obstruction and the ob-
structing ring, grossly large pale flat areas without 
mucosal folds occupying the entire ligated segment 
and failed vascular presentation appeared (Table 3, 
Figures 17 and 20-22), with even more pronounced 
severe edema of the lamina propria and continuous 
diffuse edema of the submucosa as well as pronounced 
dilatation and stasis of the submucosal blood vessels. 
This effect was associated with mild edema of the 
Figure 11  IC + RL rats (controls) at 15 min reperfusion time. At 1 min 
reperfusion time, saline (1 mL bath/rat) was applied to the reperfused 25-mm 
colon segment (lower). Relatively poor vessel presentation between arcade 
vessels is apparent in the full colon segment (upper); colon segment cleaned 
with water (middle); progressively appearing, extremely large pale areas without 
mucosal folds upon colon opening before sacrifice (lower). 
Figure 12  IC + RL rats (BPC 157-treated rats) at 15 min reperfusion time. 
At 1 min reperfusion time, BPC 157 (10 μg/kg, 2 µg/mL bath/rat) was applied 
to the reperfused 25-mm colon segment (lower). Increasing vessel presentation 
between arcade vessels is apparent in the full colon segment (upper); colon 
segment cleaned with water (middle); fully recovered mucosa and mucosal 
folds upon colon opening before sacrifice (lower).
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lamina propria and diffuse mild-to-intermediate edema 
of the submucosa, with collagen formation, one week 
later on day 10 after ligation (Figure 25A). Stasis of 
the submucosal blood vessels was also present (Figure 
25A). In these samples, the rugae are broadened and 
flattened, so the mucosa appears macroscopically 
flattened (Figure 17). By contrast, BPC 157-treated 
Table 3  Assessment of lesions in rats with obstruction of the left colic artery and vein for 10 d via  two ligations; the animals 
underwent additional colon obstruction for the first 3 d 
Medication (/kg, 1 ml bath/
rat) at the 25-mm blood-flow- 
deprived colon segment
Pale areas without mucosal folds as a 
percentage of the entire area of the blood-
deprived colon segment means ± SD
Number of gross 
mucosal defects, 
mean ± SD
Colon diameter, 
mean ± SD
Adhesion severity
scored 0-2,
Min/Med/Max
0.9% NaCl (control) 125 ± 10 4 ± 1 36 ± 8 2/2/2002
BPC 157 (10 µg)   10 ± 2a 0 ± 0a     9 ± 1a 0/1/1a
They received BPC 157 or saline bath on day 3, immediately after the additional colon obstruction was removed. The animals were assessed one week 
thereafter, on day 10 after ligation. Pale flat areas without mucosal folds were measured and are expressed as the percentage of the entire area of the blood-
deprived colon segment (mean ± SD). Number of gross mucosal defects; mean ± SD; colon diameter, mean ± SD; adhesion severity, scored 0-2 (Min/Med/
Max, respectively). aP < 0.05 at least vs control.
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Figure 15  NO levels in the colon tissue of IC + RL rats after 15 min of 
reperfusion, determined using the Griess reaction. At 1 min reperfusion 
time, BPC 157 (10 μg/kg, 2 μg/1 mL bath/rat) or an equal volume of a saline 
bath (controls) was applied to the reperfused 25-mm colon segment. aP < 0.05 
vs saline; cP < 0.05 vs healthy colon.
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Figure 16  Malondialdehyde levels in the colon tissue of IC + RL rats 
after 15 min of reperfusion, determined by quantifying thiobarbituric acid 
reactivity as malondialdehyde equivalents. At 1 min reperfusion time, BPC 
157 (10 μg/kg, 2 μg/1 mL bath/rat) or an equal volume of a saline bath (controls) 
was applied to the reperfused 25-mm colon segment. aP < 0.05 vs saline; cP < 
0.05 vs healthy colon.
Duzel A et al. BPC 157 and colitis/ischemia in rats
100
80
60
40
20
0
NO (nmol/mg protein), means ± SD
a
c
Healthy
colon
control
Saline
bath
BPC 157 (μg)
bath
Left colic artery 
and vein-ligation, 15 min
Figure 13  NO levels in the colon tissue of IC rats at 15 min ligation time 
determined using the Griess reaction. BPC 157 (10 μg/kg, 1 mL bath/rat) or 
an equal volume of a saline bath (controls) was applied to the 25-mm blood-
flow-deprived colon segment. aP < 0.05 vs saline; cP < 0.05 vs healthy colon.
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Figure 14  Malondialdehyde levels in the colon tissue of IC rats at 15 min 
ligation time, determined by quantifying thiobarbituric acid reactivity 
as malondialdehyde equivalents. BPC 157 (10 μg/kg, 1 ml bath/rat) or an 
equal volume of a saline bath (controls) was applied to the 25-mm blood-flow-
deprived colon segment. aP < 0.05 vs saline; cP < 0.05 vs healthy colon.
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rats grossly presented almost completely spared 
mucosa (Figure 20), with mild edema of the lamina 
propria and practically no edema of the submucosa 
(Figure 25B). Stasis of the submucosal blood vessels 
was also present but to a much lesser extent than in 
controls. The rugae were histologically well formed, 
only occasionally displaying slight broadening. There 
was the minimal apparent formation of new collagen 
fibers in the submucosa (Figure 25B).
In summary, these results show that BPC 157 
protects colon tissue from the endothelial damage 
induced by ischemia and reperfusion. The cytoprotective 
effect of BPC 157 against colonic ischemia/reperfusion-
mediated mucosal damage is associated with the 
activation of the collateral circulation, which circumvents 
obstructed sites and results in the resolution of 
the obstruction, reduction of oxidative stress and 
normalization of NO synthesis.
DISCUSSION
We demonstrated that well-placed arcade vessels 
respond poorly to the increased demands that occur 
upon blood supply deprivation, reperfusion or additional 
bowel obstruction. Thus, the particular susceptibility of 
the colon to insufficient vascular perfusion[1] mandates 
that the main focus of the treatment of such conditions 
should be bypassing one or more of the vascular 
obstructions. Then, the main focus is maintaining vessel 
function upon the first innate reperfusion (as evidenced 
by an initial innate recovery while the blood supply is 
deprived) in IC rats [which is also applicable much later 
with additional bowel obstruction (IC + OB rats)], and 
subsequently upon massive reperfusion following the 
removal of vascular obstruction(s) (IC + RL rats). 
Based on this reasoning, therapy for ischemic colitis 
was administered once at early ligation-time (IC-rats) or 
alternatively at early post-ligation-time (IC + RL rats). 
In some animals, the therapy was administered once at 
a later time after additional colon obstruction (IC + OB 
rats). BPC 157 therapy was shown to cure rat ischemic 
colitis in both the very early and late time points and 
under diverse harmful conditions (short-lasting blood 
deprivation (IC rats) vs reperfusion (IC + RL rats) vs 
long-lasting blood deprivation and additional bowel 
obstruction (IC + OB rats)). Obviously, such BPC 157 
therapy involves analogous cytoprotection/endothelium 
mechanisms[2-8,12-16,20], such as the cytoprotective 
response that was previously highlighted in original 
stomach cytoprotection studies of cytoprotective 
Figure 17  IC + OB rats that underwent additional colon obstruction for three days presented severely impaired gross arcade vessels immediately after the 
additional colon obstruction was removed (A, before therapy, upper); after saline bath application, they exhibited an increasing disappearance of arcade 
vessels, particularly on the dorsal side of the colon (B, 5 min after therapy, lower). The images were obtained using a USB microscope camera.
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agents in general and of BPC 157 specifically[12-16,20] in 
the immediate post-injury time period[12-16,20]. These 
results may underlie the aforementioned response for 
both ischemic and reperfusion injuries. The effects of 
BPC 157 may be usefully upgraded and accordingly 
rendered advantageous for arcade collateralization and 
for bypassing obstructive defects, thereby resulting in 
recovery throughout the course of ischemic colitis.
Thus, influencing not only the early period (which 
has not been validated before in studies of ischemic 
colitis lesions[17-19]) but also the later period should also 
be crucial in determining how to treat more complex 
ischemic colitis lesions. Interestingly, in rats with a 
prolonged obstruction of blood vessels that underwent 
additional colon obstruction due to a ring around the 
colon (IC + OB rats), the evidence suggests that a 
bath administration of BPC 157 immediately (IC rats) 
or shortly thereafter (IC + RL rats) produced a be-
neficial effect and that the effect was even greater 
when BPC 157 was administered later (IC + OB rats).
Notably, a post-injury course that is not reversed 
always presents a devastating progression. In cases 
in which the blood vessels disappeared with blood 
deprivation and did not recover with reperfusion, 
extremely large pale mucosal areas, flat and without 
folds, were found. In IC and IC + RL rats, ischemia/
reperfusion injury[9,10] increased and increased dra-
matically, respectively, whereas the MDA oxidative 
stress levels progressively increased, NO tissue values 
decreased with ligation and increased with ligation 
removal. 
The course of development described above is in 
sharp contrast to the observed course of ischemic 
colitis course in rats that received BPC 157 therapy. 
Instead of regularly failing in either experiment, the 
gross presentation of the blood vessels was recovered, 
and collateral blood vessels made interconnections 
that propagated toward the obstruction injury and 
bypassed it, rescuing blood flow. Severe edema of 
the lamina propria and continuous diffuse edema 
of the submucosa, pronounced dilatation and stasis 
in the submucosal blood vessels were all markedly 
attenuated. The animals in which BPC 157 therapy 
attenuated/counteracted the ischemia/reperfusion 
injury[9,10] showed no MDA oxidative stress and 
displayed normalized NO tissue values. Mucosal folds 
remained present (IC rats) or were recovered (IC + 
RL rats, IC + OB rats), and there were markedly fewer 
pale areas in both the short and long periods after 
ligation. At the end of the experiment, these animals 
displayed mucosa that was almost completely spared, 
with no ulceration, and the otherwise regular perilous 
Figure 18  IC + OB rats that underwent additional colon obstruction for the first three days presented severely impaired gross arcade vessels immediately 
after the additional colon obstruction was removed (A, before therapy, upper); by contrast, after bath treatment with BPC 157, all of the arcade vessels 
vigorously reappeared, together with interconnecting collaterals between the arcades. Rapid recovery of blood flow also occurred, and this was especially 
evident on the dorsal side of the colon (B, 5 min after therapy, lower). The images were obtained using a USB microscope camera. 
A
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outcome of extensive pale and flattened mucosal 
areas with severe ulcerations was avoided. In addition, 
microscopic examination showed only mild edema of 
the lamina propria and practically no edema of the 
submucosa; the rugae were well formed and only 
occasionally slightly broadened, and there was minimal 
formation of new collagen fibers in the submucosa. 
These aforementioned points, with or without therapy, 
would have a NO background. 
Notably, for quick endothelium rescue, operating 
collaterals (there are rich anastomoses between 
individual vessels on both surfaces of the large 
intestine[41]) were needed for blood flow reorganization. 
This process occurred in rats with obstructed vessels 
and with vessels that used to be obstructed, after BPC 
157 therapy. By contrast, in the experiments in which 
the course of ischemia was not reversed, decreased 
NO levels in the colon tissue appeared as an immediate 
heavy loss of endothelial cells from the vascular wall, 
which resulted in a lower eNOS production ability[42]. 
Similarly, the endothelium has general significance; 
failure[43] due to oxidative stress regularly appears as a 
result of the lysis of endothelial cells[9,10], and it may be 
further aggravated by additional reperfusion. Together, 
these reflect first a sudden decrease of colonic blood 
supply[1] and inadequate eNOS system function[2]. 
Subsequently, when the ligation is removed, the 
massive induced reperfusion likely shifts the tissue 
toward a state of noxious inducible isozyme or 
vascular wall and other tissue cell damage[44]. These 
developments can hardly be prevented spontaneously 
unless a specific agent such as BPC 157[2-8] is used as a 
therapeutic to produce a rapid and persistent recovery 
of vascular function. 
BPC 157 was shown to restore endothelial inte-
grity and to actually reverse most of the oxidative 
damage, even during reperfusion and exaggerated 
reperfusion. This effect was noticeable in IC rats and 
even more noticeable in IC + RL rats. The effect of 
BPC 157 is not like reperfusion injury, which must 
be regularly ameliorated by interventions initiated 
at the end of the ischemic period[45]. BPC 157 was 
previously shown to have a beneficial effect and 
to induce NO release in gastric mucosa from rat 
stomach tissue homogenates[46,47]. This effect occurred 
even under conditions in which L-arginine was not 
effective, a finding that could be generalized to other 
tissues[3,46,47]. Additionally, various free-radical-induced 
lesions in other organs were counteracted by BPC 
157 administration[45,48,49]. The pentadecapeptide BPC 
157 contains four carboxylic groups that may act as 
possible antioxidants; all of them could be active in the 
scavenger process, and if they are reactivated (by, e.g., 
glutathione or enzymes), the overall antioxidant activity 
could be very high. Additionally, BPC 157 is present in 
most tissues, where it can bind reactive free radicals 
and inactivate them at crucial positions that other 
antioxidants cannot reach[50].
Finally, to envisage all possibilities for the invol-
vement of the NO system in colonic ischemic injury 
(opposing healing and bleeding capabilities; L-NAME 
opposes healing and decreases bleeding time, whereas 
L-arginine promotes healing and prolongs bleeding 
time[3,51]), we conducted a parallel investigation of the 
effects of NOS blockade (L-NAME) and NOS substrate 
(L-arginine) administration, which is an important point 
that should be addressed[3].
In addition to experiments in which blood flow is 
instantly interrupted by means of two ligations in rats 
Figure 19  In IC + OB rats that underwent additional colon obstruction for 
three days, colon opening revealed pale flattened areas without mucosal 
folds immediately after additional colon obstruction was removed. The 
images were obtained using a USB microscope camera. 
Figure 20  IC + OB rats underwent additional colon obstruction for three 
days; the colon was then opened before sacrifice on day 10 [i.e., one week 
after the additional colon obstruction had been removed and bath therapy 
applied (saline, upper and middle; BPC 157, lower)]. The examination 
revealed progressive worsening in the saline-treated animals (upper and 
middle) and recovery in the BPC 157-treated animals (lower) (see Figure 11). 
The control rats exhibited extremely large pale areas without mucosal folds 
covering the entire area between ligations (middle); such areas were present 
even beyond the area of the ligation (upper), together with ulcerations in the 
deprived, apparently enlarged colon segment (middle). BPC 157-treated rats 
exhibited almost completely spared mucosa (very small pale areas) and no 
ulceration; the previously ligated colon segment was of normal diameter (lower). 
The images were obtained using a USB microscope camera. 
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that underwent interventions to produce ischemic 
colitis, the relationship between BPC 157 and NO has 
been established in various experimental models and 
species. The results of these studies suggest that BPC 
157 might interfere with the effects of NOS blocking 
agent or NOS substrate application[3]. As noted in 
this study, the complex action of BPC 157 tends to 
rule out a simple effect of either the vasoconstrictor 
(L-NAME) or the vasodilator (L-arginine)[3] in the noted 
rapid presentation of blood vessels that bypass the 
two obstructions of major vessels and reestablishing 
the blood flow that was interrupted by ligation in rats 
which subjected to the ischemic colitis procedure. 
Namely, upon encountering the regular vicious course 
of double obstruction of vessels, as individual agents, 
both L-NAME and L-arginine affect the course of the 
lesion in a particular way, and neither appears to be 
completely effective. L-NAME initially caused all vessels 
to disappear more rapidly, thereby inducing larger pale 
areas, whereas L-arginine increased the number of 
vessels present but also induced larger pale areas (note 
that L-arginine, unlike BPC 157, did not produce proper 
collateral arcade interconnection). 
This effect is likely a specific aspect of the dual 
role of the NO system (L-NAME vs. L-arginine vs. 
combination of the two) (for a review, see[3,52,53]). Each 
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Figure 21  IC + OB rats. Per cent of vessels present between arcade vessels, next to the proximal ligature (arcade 0), next to the distal ligature (arcade 4), 
and within the ligation (arcade 1, 2, 3) on the dorsal side of the colon at 15 min after therapy (as 100%); mean ± SD. The gross presentation was recorded 
using a USB microscope camera. After additional colon obstruction for three days, BPC 157 (10 μg/kg, 1 mL bath/rat) or an equal volume of a saline bath was applied 
to the 25-mm blood-flow-deprived colon segment 1 min after the colon obstruction was removed. The rats were sacrificed 15 min later, and the following time points 
were assessed: A: after ligation and before therapy (1 min); B: 5 min after the application of medication; C: between 5 and 10 min after the application of medication; D: 
from 10 min after the application of medication until the end of the observation at 15 min. For clarity, the SD is not shown on the graph; the SD was never higher than 
10% of the mean. aP < 0.05 at least vs control.
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Figure 22  IC + OB rats. Per cent of vessels present between arcade vessels, next to the proximal ligature (arcade 0), next to the distal ligature (arcade 4), 
and within the ligated area (arcade 1, 2, 3) on the ventral side of the colon 15 min after therapy (as 100%); mean ± SD. The gross presentation was recorded 
using a USB microscope camera. After additional colon obstruction for three days, BPC 157 (10 μg/kg, 1 mL bath/rat) or an equal volume of a saline bath was applied 
to the 25-mm blood-flow-deprived colon segment 1 min after the colon obstruction was removed. The rats were sacrificed 15 min later, and the following time points 
were assessed: A - after ligation and before therapy (1 min); B - 5 min after the application of medication; C - between 5 and 10 min after the application of medication; 
D - from 10 min after the application of medication until the end of the observation at 15 min.  For clarity, the SD is not shown on the graph; the SD was never higher 
than 10% of the mean. aP < 0.05 at least vs control.
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of these effects is specific (i.e., NO-related) because 
when they were administered together, L-NAME and 
L-arginine regularly attenuated or antagonized each 
other’s responses[3,52,53]. Likewise, the remaining serious 
pathology in the animals treated with L-NAME + 
L-arginine indicates that other system(s) (i.e., the BPC 
157 system) may function along with the NO system, 
which was previously supposed to be inactivated by 
the combined action of L-NAME and L-arginine[3,52,53]. 
In this view, BPC 157 would be effective regardless 
of whether the NO system is inactivated (L-NAME + 
L-arginine), overstimulated (L-arginine) or blocked 
(L-NAME). Thus, BPC 157 may consolidate the 
stimulatory and inhibitory effects of the NO system 
to produce more effective healing (i.e., by promoting 
the interconnection of arcade vessels to bypass major 
obstructions)[3]. This rapid recruitment of existing 
blood vessels that would otherwise respond poorly to 
increased demands following ongoing harmful events 
may indicate that BPC 157 also affects several other 
molecular pathways[11,25-29], the effects which were seen 
at the later time point. In particular, the immediate 
recovery of collaterals and bypassing of the obstruction, 
a feature noted in the present study, and the rapid 
reestablishment of blood flow in both the ischemic 
and reperfusion conditions may be responsible for its 
subsequent strong angiogenic effect and its healing 
effects[2,22-28], which are more pronounced than those of 
standard anti-ulcer agents[23]. 
The special feature noted in the present study 
could be responsible, in particular, for the increased 
expression and internalization of VEGFR2, which is 
known to be essential for endothelial function, and 
the activation of the VEGFR2-Akt-eNOS signaling 
pathway[25]. Previous studies have substantiated that 
BPC 157 induces an acceleration of blood flow recovery 
and vessel number within days in rats with hind limb 
ischemia[23]. Other studies have demonstrated the 
expression of growth hormone receptor at both the 
mRNA and protein levels and have shown that BPC 157 
regulates the phosphorylation of extracellular-signal-
regulated kinases 1 and 2 (ERK1/2) as well as their 
downstream targets, including c-Fos, c-Jun, and Egr-1, 
key molecules involved in cell growth, migration, and 
angiogenesis[11,25-29]. BPC 157 also induced expression 
of the Egr-1 gene and its co-repressor gene NaB2, 
suggesting that it may serve as part of a feedback 
system[29]. Together, these findings indicate how 
complex the BPC 157 pathways may be, pathways 
that remain to be further defined. 
The above considerations suggest that two ph-
armacologically distinct mechanisms with opposite 
A
B
Figure 23  Characteristic microscopic appearance of the colon in IC (A, control) rats and BP 157-treated IC rats (B) 15 min after ligation. HE, 4 × objective 
(left) and 10 × objective (right). A: Severe edema of the lamina propria and continuous diffuse edema of the submucosa can be observed. Pronounced dilatation and 
stasis of the submucosal blood vessels is also present. B: Mild edema of the lamina propria and focally present mild-to-intermediate edema of the submucosa can be 
observed. Although stasis of the submucosal blood vessels is present, the dilatation of the veins appears to be less pronounced.
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effects on the same signaling pathway are involved in 
a normally unresolvable physiological failure (complete 
obstruction (ligation) of vessels and ischemia due 
to a cause that could be not removed, inadequate 
rescue and unable to heal). Additionally, in practice, 
this means that two distinct end points should both 
be overwhelmed to produce the effects seen in 
rats that received BPC 157 application[3]. Notably, 
A
B
Figure 25  Microscopic appearance of the colon in IC + OB rats (A, control) and BPC 157-treated IC + OB rats (B) after additional colon obstruction for 
three days one week after the additional colon obstruction was removed. Control (saline bath); 10 d; BPC 157, 10 d. HE, 4 × objective (left); 10 × objective 
(right).  A: Mild edema of the lamina propria and diffuse mild-to-intermediate edema of the submucosa, along with the formation of collagen, can be observed. Stasis 
of the submucosal blood vessels is also present. The rugae are broadened and flattened, so the mucosa appears flattened macroscopically. B: Mild edema of the 
lamina propria and practically no edema of the submucosa is observed. Stasis of the submucosal blood vessels is also present but to a much lesser extent than in the 
controls. The rugae are histologically well formed and only occasionally slightly broadened. There is minimal formation of new collagen fibers in the submucosa.
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Figure 24  In IC + RL rats, 15 min of ligation followed by 15 min of full reperfusion period resulted in the appearance of even more mucosal and 
submucosal edema as well as more pronounced cyanosis (controls, upper, HE, 4 × objective). This was consistently attenuated by BPC 157 treatment after the 
initiation of reperfusion (lower, HE, 4 × objective).
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BPC 157 instantly prevents and reverses L-NAME-
induced hypertension as well as L-arginine-induced 
hypotension[46]. After amputation and/or anticoagulant 
application, BPC 157 counteracts prolonged bleeding 
and thrombocytopenia; it also counteracts the side 
effects of both L-NAME-(thrombocytopenia) and 
L-arginine (prolonged bleeding, thrombocytopenia)[51]. 
Additionally, in pupil dilation assays, a common point of 
action of L-NAME/L-arginine was noted (in miosis, both 
L-NAME and L-arginine antagonized the response to the 
other); this effect can be explained by an interaction 
with the cholinergic system[54]. BPC 157 counteracts the 
actions of both L-NAME (miosis) and L-arginine (miosis); 
interestingly, BPC 157 counteracts atropine-induced 
mydriasis as well[54]. 
The pentadecapeptide BPC 157 was also shown 
to counteract peritonitis and adhesion formation and 
to have a beneficial effect in diverse intestinal lesion 
models[30,36-40]. This particular activity is supported 
by the variety of beneficial effects of BPC 157 noted 
in colitis lesion studies[2-7]. A likely generalization 
follows the association of models of chemically 
induced inflammation (trinitrobenzenesulfonic acid 
and dextran sodium sulfate) with a marked reduction 
in blood flow[17-19]. A further generalization may be 
that BPC 157 effectiveness over the background 
of the NO-system[3,46,51,54], immobilized (L-NAME + 
L-arginine), (over)stimulated (L-arginine) or blocked 
(L-NAME), BPC 157 prevented MDA oxidative stress 
and normalized the NO tissue values. In addition 
to its use in ulcerative colitis clinical trials[2-7] and its 
effectiveness in various models of colitis[30-35], BPC 157 
reduces high myeloperoxidase (MPO) activity in colonic 
tissue[33], heals fistulas[36-38], rescues failed anastomosis 
healing[30,34,39,40] and markedly improves intestinal 
adaptation following massive bowel resection[40]. It is 
likely that the particular molecular pathways[11,25-29] 
that have been suggested to be involved in the 
healing effects of BPC 157, as well as its recently 
demonstrated ability to cause the increased expression 
and internalization of VEGFR2 and the activation of the 
VEGFR2-Akt-eNOS signaling pathway[25], contribute to 
its action.
Finally, the aforementioned rapid and successful 
recruitment of the blood vessels during harmful events 
suggests that the application of BPC 157 may offer a 
fundamental treatment by providing the cytoprotection/
endothelium protection that is essential[2-8,12-16,20] to 
quickly restore blood supply to the ischemically injured 
area and rapidly activate collaterals during various 
harmful conditions such as vascular obstruction, short-
lasting blood deprivation, reperfusion, long-lasting blood 
deprivation and additional bowel obstruction. 
COMMENTS
Background
Stable gastric pentadecapeptide BPC 157 would provide new insights in the 
treatment of colitis and ischemia and reperfusion. Likely, gastric cytoprotection 
and ischemic colitis (IC) lesions may have analogous therapy. Thereby, 
prototype cytoprotective agent gastric pentadecapeptide BPC 157, which has 
been used in trials for ulcerative colitis and now for multiple sclerosis, would 
rescue IC lesions in rats (IC rats). We studied the cytoprotective mechanism of 
BPC 157 because cytoprotection and cytoprotective agents restore the integrity 
of damaged stomach epithelium by rapidly rescuing damaged endothelium. 
This effect would involve the NO system. BPC 157 would be subsequently 
shown to be effective in IC rats underwent full reperfusion (removed ligations 
(RL) (IC + RL rats) and IC rats with additional colon obstruction (OB) (IC + OB 
rats).
Research frontiers
The main focus of the intervention was that BPC 157 rapidly activates 
collaterals due to its particular direct and rapid effect on vessel presentation, the 
bypassing of one or more of the vascular obstructions and thereby achieving a 
therapeutic effect. 
  The next focus was on NO-system, the effect of NO system agents in IC 
rats, NOS blocker L-NAME and/or NOS substrate, L-arginine; in colon tissue, 
assessing NO levels and oxidative stress (MDA levels) (as result of the lysis 
of endothelial cells) and ischemia/reperfusion injury, both as a spontaneous 
course [when blood supply was deprived via ligation (IC rats)] and a more 
exaggerated course [after ligation removal (IC + RL rats)] in immediate post-
ligation time. Notably, although the NO system is largely implicated in stomach 
cytoprotection and colitis lesions, the application of L-NAME (a vasoconstrictor) 
and/or L-arginine (a vasodilator) has not been investigated with respect to the 
immediate presentation of the blood vessels after a segment of left colic artery 
and vein was occluded by two ligations. By contrast, BPC 157 largely interacts 
with the NO system in various models and species, as shown in cytoprotection 
studies, in particular, studies using both L-NAME and L-arginine as individual 
agents or in combination. 
Innovations and breakthrough
We rescued rat ischemic colitis. The gastric pentadecapeptide BPC 157, which 
has been used in clinical trials for ulcerative colitis, exerted rapid cytoprotective 
endothelium rescue against the disabled left colic artery and vein after blood 
deprivation via two ligations and during reperfusion (ligations removed). By 
bypassing obstructions, quickly rescuing blood supply, rapidly activating 
collaterals, and restoring arcade interconnections, as a new integrative 
beneficial effect, BPC 157 prevented the occurrence of pale lesions without 
mucosal folds and normalized the levels of NO and MDA, two oxidative stress 
markers, in tissues. BPC 157 showed effectiveness over the NO-system 
background, immobilized (L-NAME + L-arginine), (over)stimulated (L-arginine) 
or blocked (L-NAME). Likewise, later application of BPC 157 in a bath treatment 
to rats with pertinently obstructed vessels that underwent additional colon 
obstruction for three days produced a similar beneficial effect.
Applications
BPC 157 is a fundamental treatment that quickly restores blood supply to the 
ischemically injured area and rapidly activates collaterals. This effect involves 
the NO system. 
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